Zealand Pharma sued over misusing trade secrets

Two separate joint ventures never materialized for Greek biotech company Amyndas, leaving it first to ponder why, and later to blame Zealand Pharma and its US affiliate for running away with its secrets.

Adam Steensberg was the interim CEO when Zealand Pharma signed a partnership deal with Alexion, which was also a breach of confidentiality agreements a Greek firm claims | Photo: Zealand Pharma

”When biotech firms engage in the entrepreneurial equivalent of musical chairs, one firm sometimes gets left out in the cold. That is essentially what happened here.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs